Published in N Engl J Med on January 20, 2010
Cladribine Tablets After Treatment With Natalizumab (CLADRINA) | NCT04178005
A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets | NCT04550455
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). J Med Internet Res (2011) 1.39
Oral therapy for multiple sclerosis--sea change or incremental step? N Engl J Med (2010) 1.25
The risk of fracture in patients with multiple sclerosis: the UK general practice research database. J Bone Miner Res (2011) 1.22
N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis. J Biol Chem (2011) 1.21
Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol (2011) 1.18
Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol (2011) 1.15
Placebo? no thanks, it might be bad for me! Eur J Clin Pharmacol (2012) 1.13
Novel PET probes specific for deoxycytidine kinase. J Nucl Med (2010) 1.11
Retracted Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int J Mol Sci (2012) 1.11
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther (2014) 1.05
Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol (2011) 1.04
Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord (2010) 1.01
A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol (2010) 0.99
Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol (2011) 0.98
Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf (2013) 0.97
Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol (2011) 0.94
New approaches in the management of multiple sclerosis. Drug Des Devel Ther (2010) 0.92
Restoring the balance between disease and repair in multiple sclerosis: insights from mouse models. Dis Model Mech (2010) 0.92
Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One (2011) 0.92
Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol (2015) 0.92
Life issues in multiple sclerosis. Nat Rev Neurol (2010) 0.90
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Drug Des Devel Ther (2012) 0.85
Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2010) 0.85
The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology (2016) 0.84
Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN Neuro (2011) 0.84
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol (2012) 0.84
Future MS care: a consensus statement of the MS in the 21st Century Steering Group. J Neurol (2012) 0.83
Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther Adv Chronic Dis (2013) 0.83
Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. JAMA Neurol (2013) 0.83
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag (2010) 0.83
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. Drugs (2015) 0.82
Toxicities of immunosuppressive treatment of autoimmune neurologic diseases. Curr Neuropharmacol (2011) 0.82
The evolving role of the multiple sclerosis nurse: an international perspective. Int J MS Care (2011) 0.81
Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther (2011) 0.81
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis (2011) 0.81
Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice. PLoS One (2012) 0.81
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. Ther Clin Risk Manag (2013) 0.81
Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLoS One (2012) 0.80
3,3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through microRNA signaling pathways. J Pharmacol Exp Ther (2014) 0.79
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA J (2010) 0.79
Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone. ISRN Neurol (2013) 0.79
2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Clin Exp Immunol (2013) 0.79
Managing MS in a changing treatment landscape. J Neurol (2011) 0.79
Combinatorial Effect of Metformin and Lovastatin Impedes T-cell Autoimmunity and Neurodegeneration in Experimental Autoimmune Encephalomyelitis. J Clin Cell Immunol (2013) 0.79
Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets. Ther Clin Risk Manag (2010) 0.78
Clarity and strength of implications for practice in medical journal articles: an exploratory analysis. BMJ Qual Saf (2011) 0.78
Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol (2015) 0.78
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine (2017) 0.78
Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing. PLoS One (2016) 0.77
Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies. Adolesc Health Med Ther (2010) 0.77
Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis. BMC Neurol (2013) 0.77
Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis. Nat Rev Neurol (2011) 0.77
Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evid (2011) 0.77
Is serum vitamin D levels associated with disability in patients with newly diagnosed multiple sclerosis? Iran J Neurol (2013) 0.77
Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology (2013) 0.77
Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatr Dis Treat (2013) 0.76
Drugs: An injection of hope. Nature (2012) 0.76
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm (2015) 0.75
New drugs may improve, complicate treatment for multiple sclerosis. Nat Med (2010) 0.75
Oral cladribine and fingolimod for relapsing multiple sclerosis. N Engl J Med (2010) 0.75
Serum 25(OH) Vitamin D levels is not associated with disability in multiple sclerosis patients: A case-control study. Iran J Neurol (2015) 0.75
ACP Journal Club. Oral cladribine was more effective than placebo for relapsing-remitting multiple sclerosis. Ann Intern Med (2010) 0.75
Diagnosis and Management of Multiple Sclerosis in Children. Iran J Child Neurol (2016) 0.75
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Drug Des Devel Ther (2010) 0.75
Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine. J Cent Nerv Syst Dis (2012) 0.75
Oral cladribine and fingolimod for relapsing multiple sclerosis. N Engl J Med (2010) 0.75
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat (2010) 0.75
Oral disease-modifying therapies for multiple sclerosis: are we there yet? Curr Neurol Neurosci Rep (2010) 0.75
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells. PLoS One (2015) 0.75
Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. Clin Pharmacokinet (2017) 0.75
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature (2003) 5.31
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol (2007) 3.81
Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature (2005) 3.53
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache (2007) 2.75
Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) (2004) 2.54
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology (2006) 2.43
Distribution and functional impact of DNA copy number variation in the rat. Nat Genet (2008) 2.20
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology (2013) 2.08
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol (2005) 2.01
Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology (2012) 2.00
A multicenter prospective study of 3,110 consecutive cases of elective epinephrine use in the fingers and hand: the Dalhousie Project clinical phase. J Hand Surg Am (2005) 1.96
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med (2002) 1.91
Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain (2009) 1.89
The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2010) 1.89
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol (2005) 1.85
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol (2013) 1.83
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol (2010) 1.75
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (2012) 1.75
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol (2011) 1.69
Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol (2002) 1.68
Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain (2008) 1.67
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J (2011) 1.67
MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett (2011) 1.64
Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke (2008) 1.63
Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke (2006) 1.63
EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet (2010) 1.62
Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.59
A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics (2002) 1.58
Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. Biol Psychiatry (2013) 1.58
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol (2003) 1.57
Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol (2002) 1.53
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med (2003) 1.52
CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci U S A (2003) 1.51
Long-term follow-up of acute partial transverse myelitis. Arch Neurol (2012) 1.50
New perspectives in the natural history of multiple sclerosis. Neurology (2010) 1.50
A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol (2005) 1.50
Brain network connectivity assessed using graph theory in frontotemporal dementia. Neurology (2013) 1.50
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol (2013) 1.47
Integrin-linked kinase regulates endothelial cell survival and vascular development. Mol Cell Biol (2004) 1.46
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology (2009) 1.45
Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult Scler (2009) 1.41
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother (2012) 1.40
Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention. Headache (2009) 1.40
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol (2003) 1.39
Migralepsy: a new case confirming the existence of this migraine complication and proposing therapy. Neurol Sci (2012) 1.39
Patent foramen ovale closure and brain ischaemic lesions. Heart (2013) 1.39
Spontaneous intracerebral hemorrhage in Urbach-Wiethe disease. Neurology (2012) 1.39
Longitudinal Integrated Clerkship: A Student's Perspective. S D Med (2016) 1.39
Renal transposition during minimally invasive partial nephrectomy: a safe technique for excision of upper pole tumors. J Endourol (2013) 1.38
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol (2004) 1.38
Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. J Cell Sci (2006) 1.37
Multiple sclerosis registry in Germany: results of the extension phase 2005/2006. Dtsch Arztebl Int (2008) 1.33
Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol (2009) 1.30
A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage (2008) 1.30
Magnetic-resonance-based tracking and quantification of intravenously injected neural stem cell accumulation in the brains of mice with experimental multiple sclerosis. Stem Cells (2007) 1.27
Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol (2012) 1.26
Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.26
Transplanted neural stem/precursor cells instruct phagocytes and reduce secondary tissue damage in the injured spinal cord. Brain (2012) 1.26
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler (2013) 1.25
Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol (2011) 1.25
Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler (2004) 1.24
Age-related changes in conventional, magnetization transfer, and diffusion-tensor MR imaging findings: study with whole-brain tissue histogram analysis. Radiology (2003) 1.24
Marchiafava-Bignami disease: longitudinal MR imaging and MR spectroscopy study. AJNR Am J Neuroradiol (2003) 1.23
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler (2013) 1.22
Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One (2009) 1.21
A benign form of neuromyelitis optica: does it exist? Arch Neurol (2011) 1.21
Optical coherence tomography in neuromyelitis optica. Arch Neurol (2008) 1.20
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci (2005) 1.20
Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol (2005) 1.19
A versatile method for cell-specific profiling of translated mRNAs in Drosophila. PLoS One (2012) 1.19
Animal models of ischemic stroke. Part two: modeling cerebral ischemia. Open Neurol J (2010) 1.18